"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 1 | 2 |
| 1994 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 3 | 0 | 3 |
| 2002 | 6 | 2 | 8 |
| 2003 | 11 | 5 | 16 |
| 2004 | 6 | 6 | 12 |
| 2005 | 4 | 7 | 11 |
| 2006 | 2 | 5 | 7 |
| 2007 | 8 | 2 | 10 |
| 2008 | 5 | 5 | 10 |
| 2009 | 7 | 8 | 15 |
| 2010 | 9 | 6 | 15 |
| 2011 | 10 | 7 | 17 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 4 | 9 |
| 2014 | 4 | 1 | 5 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 3 | 4 |
| 2017 | 6 | 2 | 8 |
| 2018 | 3 | 4 | 7 |
| 2019 | 4 | 5 | 9 |
| 2020 | 2 | 2 | 4 |
| 2021 | 6 | 5 | 11 |
| 2022 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan. Value Health Reg Issues. 2022 Sep; 31:34-38.
-
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 07; 11(14):2790-2800.
-
The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity. Nat Commun. 2022 01 17; 13(1):187.
-
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022 01 20; 40(3):282-293.
-
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? J Clin Oncol. 2021 11 01; 39(31):3423-3426.
-
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. Lung Cancer. 2021 10; 160:152-165.
-
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mol Cancer Ther. 2021 10; 20(10):1820-1835.
-
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer. 2021 10 01; 127(19):3622-3630.
-
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 07 12; 39(7):989-998.e5.
-
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021 09; 32(9):1101-1110.